Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
PURPOSE: Platinum chemotherapy can be considered to treat metastatic castration-resistant prostate cancer (mCRPC) with features of neuroendocrine differentiation. However, platinum compounds are generally only applied after the failure of multiple prior-line treatment options. This study investigated whether acquired resistance against ionizing radiation or docetaxel chemotherapy-two commonly applied treatment modalities in prostate cancer-influences the cisplatin (CDDP) tolerance in mCRPC cell line models.
METHODS: Age-matched parental as well as radio- or docetaxel-resistant DU145 and PC-3 cell lines were treated with CDDP and their sensitivity was assessed by measurements of growth rates, viability, apoptosis, metabolic activity and colony formation ability.
RESULTS: The data suggest that docetaxel resistance does not influence CDDP tolerance in all tested docetaxel-resistant cell lines. Radio-resistance was associated with sensitization to CDDP in PC-3, but not in DU145 cells. In general, DU145 cells tolerated higher CDDP concentrations than PC-3 cells regardless of acquired resistances. Furthermore, non-age-matched treatment-naïve PC-3 cells exhibited significantly different CDDP tolerances.
CONCLUSION: Like patients, different mCRPC cell lines exhibit significant variability regarding CDDP tolerance. The presented in vitro data suggest that previous radiation treatment may be associated with a moderate sensitization to CDDP in an isogenic and age-matched setting. Therefore, previous radiotherapy or docetaxel chemotherapy might be no contraindication against initiation of platinum chemotherapy in selected mCRPC patients.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 1313-1324 |
Seitenumfang | 12 |
Fachzeitschrift | Journal of cancer research and clinical oncology |
Jahrgang | 148 |
Ausgabenummer | 6 |
Frühes Online-Datum | 12 Jan. 2022 |
Publikationsstatus | Veröffentlicht - 1 Juni 2022 |
Peer-Review-Status | Ja |
Externe IDs
Scopus | 85122829354 |
---|---|
WOS | 000741943700002 |
unpaywall | 10.1007/s00432-022-03914-5 |
Mendeley | 2843b974-0f32-35b7-b979-e036ad9d9b0a |
ORCID | /0000-0003-3717-3637/work/141545158 |
ORCID | /0000-0002-5247-908X/work/142241927 |
Schlagworte
Ziele für nachhaltige Entwicklung
ASJC Scopus Sachgebiete
Schlagwörter
- Cisplatin, Docetaxel, NEPC, Prostate cancer, Radiotherapy, mCRPC